The global chronic hepatitis B treatment market is witnessing significant development. This phenomenon can be linked to a growing of factors, including an aging population, enhanced diagnostic capabilities, and escalating awareness about the disease. The market is in addition driven by developments in treatment options, such as antiviral medication